Lee Schwartzberg, MD, FACP | Authors


Expert Discusses HER2 Selective Kinase Inhibitors in Heavily Pretreated Breast Cancer

February 08, 2021

During a Targeted Oncology Case-Based Peer Perspectives virtual event, Lee Schwartzberg, MD, medical oncologist, West Cancer Center and Research Institute, discussed the therapeutic options for a 39-year-old woman with HER2-positive breast cancer who was heavily pretreated.

Effective Management of CINV Improves Response to Treatment

November 09, 2017

The goal of selecting optimal antiemetic therapy continues to be a moving target with the emergence of newer agents and patient-related risk factors, as well as the rapid evolution of guidelines for the management of chemotherapy-induced nausea and vomiting.